TB vaccine alert creates added HIV screening needs
This article was originally published in Clinica
Executive Summary
There is an important new reason to conduct prenatal and perinatal testing for HIV whenever there is a risk of vertical transmission. Infected infants are at "considerably higher risk" of contracting tuberculosis (TB) from the standard BCG (bacillus Calmette-Guérin) vaccine than previously estimated, according to research published today in the Bulletin of the World Health Organization. The Stellenbosch University (Tygerberg, South Africa) researchers recommend delaying vaccination until HIV status is known, and say there is an urgent need for further research to determine the risk-benefits involved. BCG is used globally to protect people from TB – some 75% of all children born worldwide (130 million in 2002) receive the vaccine. An estimated 390,000-420,000 children a year acquire HIV by the age of 15.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.